NovoCure (NVCR) News Today $16.86 +0.38 (+2.31%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period NovoCure Limited (NASDAQ:NVCR) Receives $26.17 Average Target Price from AnalystsNovember 21 at 4:49 AM | americanbankingnews.comNovocure participates in a conference call with JPMorganNovember 16, 2024 | markets.businessinsider.comNovoCure Limited (NASDAQ:NVCR) Given Average Rating of "Moderate Buy" by BrokeragesShares of NovoCure Limited (NASDAQ:NVCR - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six analysts that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating toNovember 16, 2024 | marketbeat.comNovoCure Limited (NASDAQ:NVCR) Shares Sold by Baillie Gifford & Co.Baillie Gifford & Co. lowered its position in NovoCure Limited (NASDAQ:NVCR - Free Report) by 1.7% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 1,659,314 shares of the medical equipment provider's stock after selling 28,207 shares durNovember 13, 2024 | marketbeat.comNovoCure Limited (NASDAQ:NVCR) Shares Purchased by Nordwand Advisors LLCNordwand Advisors LLC raised its position in NovoCure Limited (NASDAQ:NVCR - Free Report) by 100.0% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 3,029,824 shares of the medical equipment provider's stock after buying an additional 1,514,824 shares duringNovember 9, 2024 | marketbeat.comInsider Selling: NovoCure Limited (NASDAQ:NVCR) Insider Sells 810 Shares of StockNovember 5, 2024 | insidertrades.comMichal Nath Puri Sells 810 Shares of NovoCure Limited (NASDAQ:NVCR) StockNovoCure Limited (NASDAQ:NVCR - Get Free Report) insider Michal Nath Puri sold 810 shares of the firm's stock in a transaction that occurred on Thursday, October 31st. The stock was sold at an average price of $15.79, for a total transaction of $12,789.90. Following the completion of the transaction, the insider now owns 110,093 shares in the company, valued at $1,738,368.47. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.November 4, 2024 | marketbeat.comFY2024 EPS Estimates for NovoCure Increased by HC WainwrightNovoCure Limited (NASDAQ:NVCR - Free Report) - Investment analysts at HC Wainwright increased their FY2024 earnings per share (EPS) estimates for NovoCure in a research report issued to clients and investors on Wednesday, October 30th. HC Wainwright analyst E. Bodnar now anticipates that the mediNovember 4, 2024 | marketbeat.comNovoCure Limited (NASDAQ:NVCR) Q3 2024 Earnings Call TranscriptNovember 2, 2024 | msn.comWhat is Wedbush's Forecast for NovoCure FY2024 Earnings?NovoCure Limited (NASDAQ:NVCR - Free Report) - Wedbush lifted their FY2024 EPS estimates for shares of NovoCure in a report released on Wednesday, October 30th. Wedbush analyst D. Nierengarten now forecasts that the medical equipment provider will earn ($1.26) per share for the year, up from theiNovember 1, 2024 | marketbeat.comNovoCure’s Strong Q3 and Leadership Changes in 2024October 31, 2024 | finance.yahoo.comHC Wainwright Reiterates Buy Rating for NovoCure (NASDAQ:NVCR)HC Wainwright reissued a "buy" rating and issued a $30.00 price target on shares of NovoCure in a research report on Thursday.October 31, 2024 | marketbeat.comNovoCure Beats Q3 Revenue, EPS EstimatesOctober 31, 2024 | fool.comNovoCure Ltd (NVCR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ...October 31, 2024 | uk.finance.yahoo.comStrong Financial Performance and Promising Growth Drive Buy Rating for NovoCureOctober 31, 2024 | markets.businessinsider.comNovoCure (NVCR) Q3 2024 Earnings Call TranscriptOctober 31, 2024 | msn.comNovoCure (NASDAQ:NVCR) Trading Down 7.1% - What's Next?NovoCure (NASDAQ:NVCR) Trading Down 7.1% - What's Next?October 30, 2024 | marketbeat.comNovoCure Limited (NVCR) Q3 2024 Earnings Conference Call TranscriptOctober 30, 2024 | seekingalpha.comNovocure Names Christoph Brackmann Chief Financial OfficerOctober 30, 2024 | marketwatch.comNovocure Reports Third Quarter 2024 Financial ResultsOctober 30, 2024 | finance.yahoo.comNovocure Appoints Christoph Brackmann as Chief Financial OfficerOctober 30, 2024 | businesswire.comSemanteon Capital Management LP Purchases New Position in NovoCure Limited (NASDAQ:NVCR)Semanteon Capital Management LP purchased a new stake in shares of NovoCure Limited (NASDAQ:NVCR - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 73,729 shares of the medical equipment provider's stock, valued at apOctober 28, 2024 | marketbeat.comPiper Sandler Sticks to Its Buy Rating for NovoCure (NVCR)October 25, 2024 | markets.businessinsider.comNovoCure (NVCR) Set to Announce Quarterly Earnings on WednesdayNovoCure (NASDAQ:NVCR) will be releasing earnings before the market opens on Wednesday, October 30, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=632274)October 23, 2024 | marketbeat.comNovoCure Limited (NASDAQ:NVCR) Given Consensus Recommendation of "Moderate Buy" by BrokeragesNovoCure Limited (NASDAQ:NVCR - Get Free Report) has received an average recommendation of "Moderate Buy" from the six brokerages that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to tOctober 22, 2024 | marketbeat.comNovoCure Limited (NASDAQ:NVCR) Shares Sold by SG Americas Securities LLCSG Americas Securities LLC trimmed its holdings in NovoCure Limited (NASDAQ:NVCR - Free Report) by 87.6% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,612 shares of the medical equipment provider's stock after sellingOctober 21, 2024 | marketbeat.comFY2025 EPS Estimates for NovoCure Raised by Leerink PartnrsNovoCure Limited (NASDAQ:NVCR - Free Report) - Research analysts at Leerink Partnrs boosted their FY2025 earnings per share (EPS) estimates for shares of NovoCure in a note issued to investors on Tuesday, October 15th. Leerink Partnrs analyst J. Chang now anticipates that the medical equipment prOctober 18, 2024 | marketbeat.comNovoCure (NASDAQ:NVCR) Stock Price Down 4.5% - Time to Sell?NovoCure (NASDAQ:NVCR) Trading Down 4.5% - Here's WhyOctober 17, 2024 | marketbeat.comFDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung CancerOctober 16, 2024 | businesswire.comNovoCure’s Optune Lua Gains FDA Approval for NSCLC, Projecting Significant Sales Growth and ExpansionOctober 16, 2024 | markets.businessinsider.comNovocure shares soar 33% as FDA approves lung cancer treatmentOctober 16, 2024 | msn.comHC Wainwright & Co. Upgrades NovoCure (NVCR)October 16, 2024 | msn.comFDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer PatientsOctober 16, 2024 | finance.yahoo.comNovoCure: There Is Still More UpsideOctober 16, 2024 | seekingalpha.comNovoCure (NASDAQ:NVCR) Shares Gap Up - Time to Buy?NovoCure (NASDAQ:NVCR) Shares Gap Up - What's Next?October 16, 2024 | marketbeat.comNovoCure Sees Unusually High Options Volume (NASDAQ:NVCR)NovoCure Limited (NASDAQ:NVCR - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock investors purchased 6,407 call options on the stock. This represents an increase of 587% compared to the typical volume of 932 call options.October 16, 2024 | marketbeat.comNovoCure (NASDAQ:NVCR) Raised to "Buy" at HC WainwrightHC Wainwright raised shares of NovoCure from a "neutral" rating to a "buy" rating and lifted their price target for the company from $24.00 to $30.00 in a research report on Wednesday.October 16, 2024 | marketbeat.comFDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung CancerOctober 15, 2024 | businesswire.comThe Manufacturers Life Insurance Company Purchases 37,951 Shares of NovoCure Limited (NASDAQ:NVCR)The Manufacturers Life Insurance Company grew its position in NovoCure Limited (NASDAQ:NVCR - Free Report) by 25.3% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 187,772 shares of the medical equipment provider's stock after buying an additional 37,951 sharesOctober 9, 2024 | marketbeat.comNovoCure's Stock Stagnates Amid Lack Of Progress Beyond GBMOctober 8, 2024 | seekingalpha.comNovoCure (NASDAQ:NVCR) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comAQR Capital Management LLC Acquires 302,351 Shares of NovoCure Limited (NASDAQ:NVCR)AQR Capital Management LLC lifted its holdings in shares of NovoCure Limited (NASDAQ:NVCR - Free Report) by 234.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 431,445 shares of the meOctober 4, 2024 | marketbeat.comNovoCure (NASDAQ:NVCR) Trading Down 4%NovoCure (NASDAQ:NVCR) Stock Price Down 4%October 3, 2024 | marketbeat.comNovocure to Report Third Quarter 2024 Financial ResultsOctober 1, 2024 | finance.yahoo.comNovoCure (NASDAQ:NVCR) Given New $18.00 Price Target at Evercore ISIEvercore ISI reduced their price target on shares of NovoCure from $21.00 to $18.00 and set an "in-line" rating on the stock in a report on Tuesday.October 1, 2024 | marketbeat.comMarshall Wace LLP Sells 272,053 Shares of NovoCure Limited (NASDAQ:NVCR)Marshall Wace LLP reduced its stake in NovoCure Limited (NASDAQ:NVCR - Free Report) by 35.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 497,474 shares of the medical equipment provider's stock after sellSeptember 30, 2024 | marketbeat.comScientech Research LLC Makes New $645,000 Investment in NovoCure Limited (NASDAQ:NVCR)Scientech Research LLC bought a new stake in shares of NovoCure Limited (NASDAQ:NVCR - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 37,647 shares of the medical equipment provider's stock, valued at apprSeptember 29, 2024 | marketbeat.comHsbc Holdings PLC Sells 75,530 Shares of NovoCure Limited (NASDAQ:NVCR)Hsbc Holdings PLC decreased its stake in shares of NovoCure Limited (NASDAQ:NVCR - Free Report) by 50.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 73,818 shares of the medical equipment provideSeptember 28, 2024 | marketbeat.comNovoCure Limited (NASDAQ:NVCR) Shares Sold by Cubist Systematic Strategies LLCCubist Systematic Strategies LLC cut its position in shares of NovoCure Limited (NASDAQ:NVCR - Free Report) by 61.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 354,033 shares of the medical equipment provider's stock after selling 559,768September 27, 2024 | marketbeat.comNovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Moderate Buy" by AnalystsNovoCure Limited (NASDAQ:NVCR - Get Free Report) has received an average rating of "Moderate Buy" from the six research firms that are covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to thSeptember 27, 2024 | marketbeat.com Get NovoCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter. Email Address Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soon Click here to watch it now. NVCR Media Mentions By Week NVCR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NVCR News Sentiment▼0.670.45▲Average Medical News Sentiment NVCR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NVCR Articles This Week▼24▲NVCR Articles Average Week Get NovoCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Nevro News Bausch + Lomb News Inspire Medical Systems News PROCEPT BioRobotics News Axonics News Envista News Inari Medical News TransMedics Group News LivaNova News Enovis News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NVCR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share NovoCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
